Eric Dube: And the second question. Thank you, Peter. Sorry, operator. We’ve got two additional questions from the last questioner. So Chris, I’ll hand these over to you. So can you explain the Thiola generic dynamics on revenue as well as the $65 million anticipated payment?
Chris Cline: Yes. Thanks for the questions, Ed. On the first one with Thiola, that’s not actually related to, the activity isn’t related to the generic entry at this point. What we see right now is the typical growth to net adjustments in the first quarter of the year that we’ve seen in historical years. So that’s really the driving difference in Q4 to Q1. And we would anticipate that that levels out similar as it has in years past. And then on the second one, Ed, you have it right that the $65 million IPR&D expense this quarter is related to the first patient dosed in the Phase III Harmony Study Effective Admin.
Ed Arce: Great. Thanks so much.
Operator: Your next question comes from the line of Allison Bratzla with Piper Sandler. Allison Bratzla, your line is open.
Allison Bratzla: Hi, good afternoon. Congrats on a nice quarter, and thanks for squeezing me in. You mentioned the recent SPARTAN study update in newly diagnosed IgAN patients. I’m just hoping you could talk about KOL and nephrologists’ reaction to that. And just, is it your sense that docs need to see any additional clinical data to really catalyze or drive widespread earlier line use of FILSPARI?
Eric Dube: Yes. So Allison, maybe I’ll just comment on one thing that Peter mentioned on this call, as well as on our prior call. We’re very pleased to see that the majority of thought leaders within the US are currently prescribing FILSPARI to patients with IgAN in their practice, and I think that that gives a great confidence in the overall profile. Jula, why don’t you talk a little bit more about the potential impact or the reaction that you’re hearing to the SPARTAN results to date?
Jula Inrig: Thanks for the question. I think it’s very exciting to see the data that we are generating across our program which is not just SPARTAN which is earlier treatment, but also combination treatment. And that supports that we believe that FILSPARI should be foundational care and also that patients should be treated earlier in their disease. I think people are very excited about what we’ve put out around Sparsentan that it’s newly diagnosed patients who have not been treated earlier in their disease course even slightly lower ranges of protein and higher EGFR and that if you treat early that you can get patients two-thirds into complete remission, stable EGFR, nearly 80% reduction in proteinuria. People are very excited about this data and we’re going to continue to publish more.
We’ve done 36 weeks. We’ll have one-year data and further data as well as biopsy data. But it really places and reiterates that FILSPARI isn’t just targeting damage that’s already occurred and helping with the remodel, but it can help prevent the damage that occurs as you have IgAN nephropathy deposition because we are treating very early in the disease. And it shouldn’t be fair for patients who just have advanced stage kidney disease. So a lot of encouragement around that and excitement as more data comes out later this year around it.
Operator: Ladies and gentlemen, this concludes the question-and-answer session of today’s conference call. I’ll hand the call back over to Anne.
Anne Crotteau: Great. Thank you everyone for joining us for our first quarter 2024 financial results call. We look forward to providing additional updates on our progress. Have a great rest of your day.
Operator: This does conclude today’s call. Thank you for your participation. You may now disconnect.
